PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.47%
Both yoy net incomes decline, with TRAW at -240.65%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-1.12%
Negative yoy D&A while TRAW is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
11.01%
Deferred tax of 11.01% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
20.13%
SBC growth while TRAW is negative at -0.69%. John Neff would see competitor possibly controlling share issuance more tightly.
171.56%
Well above TRAW's 75.62% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.25%
A yoy AP increase while TRAW is negative at -1.42%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
60.10%
Growth well above TRAW's 61.90%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
20.13%
Lower 'other non-cash' growth vs. TRAW's 62.93%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
23.86%
Some CFO growth while TRAW is negative at -52.77%. John Neff would note a short-term liquidity lead over the competitor.
-1272.99%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1272.99%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-196.64%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1193.74%
We slightly raise equity while TRAW is negative at -100.01%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.